Canada Consults On Disclosure Of Confidential Info On Approved Products
This article was originally published in Clinica
Executive Summary
Health Canada is seeking feedback on a draft guideline that explains how the health minister intends to use new discretionary powers to disclose confidential business information (CBI) about approved drugs and medical devices, without prior permission from affected companies, to help health researchers and practitioners in their work and to improve patient safety.
You may also be interested in...
Canada’s Plan To Proactively Release Device Clinical Data Draws Flak From US Medtech
US medtech industry association AdvaMed is concerned that Health Canada’s plan to proactively release certain clinical information in medical device applications could undercut innovation.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.